These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 26885621)

  • 1. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
    Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
    Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using Serological Proteome Analysis to Identify Serum Anti-Nucleophosmin 1 Autoantibody as a Potential Biomarker in European-American and African-American Patients With Prostate Cancer.
    Dai L; Li J; Xing M; Sanchez TW; Casiano CA; Zhang JY
    Prostate; 2016 Nov; 76(15):1375-86. PubMed ID: 27418398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
    O'Rourke DJ; DiJohnson DA; Caiazzo RJ; Nelson JC; Ure D; O'Leary MP; Richie JP; Liu BC
    Clin Chim Acta; 2012 Mar; 413(5-6):561-7. PubMed ID: 22146597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.
    Dai L; Li J; Ortega R; Qian W; Casiano CA; Zhang JY
    J Immunol Res; 2014; 2014():827827. PubMed ID: 24860838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.
    Adeola HA; Soares NC; Paccez JD; Kaestner L; Blackburn JM; Zerbini LF
    Proteomics Clin Appl; 2015 Jun; 9(5-6):597-609. PubMed ID: 25708745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.
    Ummanni R; Duscharla D; Barett C; Venz S; Schlomm T; Heinzer H; Walther R; Bokemeyer C; Brümmendorf TH; Murthy PV; Balabanov S
    J Proteomics; 2015 Apr; 119():218-29. PubMed ID: 25724726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
    Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
    Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
    Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
    Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biomarkers of prostate cancer and potential for using ace produced in prostate gland for diagnosis of prostate cancer and benign prostatic hyperplasia].
    Kamalov AA; Samokhodskaya LM; Karpov VK; Okhobotov DA; Mamedov VN
    Urologiia; 2019 Jun; (2):73-81. PubMed ID: 31162906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG.
    Luna-Coronell JA; Vierlinger K; Gamperl M; Hofbauer J; Berger I; Weinhäusel A
    Proteomics; 2016 Apr; 16(8):1204-14. PubMed ID: 27089054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.
    Fawzy MS; Mohamed RH; Elfayoumi AR
    Med Oncol; 2015 Mar; 32(3):74. PubMed ID: 25698533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification analyses for prostate cancer, benign prostate hyperplasia and healthy subjects by SERS-based immunoassay of multiple tumour markers.
    Zhou L; Liu Y; Wang F; Jia Z; Zhou J; Jiang T; Petti L; Chen Y; Xiong Q; Wang X
    Talanta; 2018 Oct; 188():238-244. PubMed ID: 30029370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
    Zhao H; Zhao X; Lei T; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer.
    Wong KK; Hussain FA; Loo SK; López JI
    APMIS; 2017 Dec; 125(12):1092-1101. PubMed ID: 28972294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.